Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China
World Allergy Organization Journal, 2022 Background: Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged
Ao Wang, MD +7 more
doaj +1 more source
The future outlook on allergen immunotherapy in children: 2018 and beyond. [PDF]
, 2018 Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases.
Arasi S, Corsello G, Pajno GB, Villani A
core +2 more sources
Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]
, 2014 Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core +1 more source
Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. [PDF]
, 2015 BACKGROUND: Omalizumab is approved in the UK as add-on treatment for chronic spontaneous urticaria (CSU) in patients with inadequate response to H1-antihistamines. Ciclosporin is an established but unlicensed 3rd line option for CSU.
Ardern-Jones, MR +7 more
core +2 more sources
Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels : a pilot study [PDF]
, 2018 Background: Administration of the therapeutic anti-IgE antibody omalizumab to patients induces strong increases in IgE antibody levels. Objective: To investigate the effect of intranasal administration of major birch pollen allergen Bet v 1, omalizumab ...
Bischoff +38 more
core +1 more source
Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data [PDF]
, 2018 Background: The X‐ACT study aimed to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1‐antihistamines. Methods: In X‐ACT, a phase III, double‐
Barbosa +29 more
core +1 more source
Omalizumab and IgE in the Control of Severe Allergic Asthma
Frontiers in Pharmacology, 2022 Omalizumab, a human immunoglobulin (Ig)G1 antibody against IgE, is a therapeutic agent for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of omalizumab should be considered as an option in step 5 of treatment for ...
Yasuhiro Gon +2 more
doaj +1 more source
LINX®, a novel treatment for patients with refractory asthma complicated by gastroesophageal reflux disease: a case report. [PDF]
, 2016 BackgroundGastroesophageal reflux disease is one of the most common comorbidities in patients with asthma. Gastroesophageal reflux disease can be linked to difficult-to-control asthma.
Kenyon, Nicholas J +6 more
core +2 more sources
Therapeutic Advances in Respiratory Disease, 2018 Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that ...
Corrado Pelaia +5 more
doaj +1 more source
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad
Monaldi Archives for Chest Disease, 2020 Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the
Paolo Cameli +7 more
doaj +1 more source